tiprankstipranks
Apimeds Pharmaceuticals US, Inc. (APUS)
:APUS
US Market
APUS
Apimeds Pharmaceuticals US, Inc.
RESEARCH TOOLSreports

Apimeds Pharmaceuticals US, Inc. (APUS) Income Statement

17 Followers

Apimeds Pharmaceuticals US, Inc. Income Statement

Last quarter (Q3 2025), Apimeds Pharmaceuticals US, Inc.'s total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Apimeds Pharmaceuticals US, Inc.'s net income was $-1.78M. See Apimeds Pharmaceuticals US, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 1.28M$ 747.44K$ 639.53K$ 1.02M
Depreciation and Amortization
$ 0.00$ 0.00$ 0.00$ 0.00
EBITDA
$ -1.27M$ -739.63K$ -639.53K$ -1.02M
Operating Income
$ -1.28M$ -747.44K$ -639.53K$ -1.02M
Other Income/Expenses
$ -114.89K$ -30.26K$ -29.14K$ -6.74K
Pretax Income
$ -1.39M$ -777.69K$ -668.67K$ -1.03M
Net Income
$ -1.39M$ -777.69K$ -668.67K$ -1.03M
Per Share Metrics
Basic EPS
$ -1.20$ -0.68$ -0.58$ -0.89
Diluted EPS
$ -1.10$ -0.61$ -0.53$ -0.81
Weighted Average Shares Outstanding
 1.15M 1.15M 1.15M 1.15M
Weighted Average Shares Outstanding (Diluted)
 1.27M 1.27M 1.27M 1.27M
Currency in USD

Apimeds Pharmaceuticals US, Inc. Earnings and Revenue History